Back to top
more

Surmodics (SRDX)

(Delayed Data from NSDQ)

$26.17 USD

26.17
30,626

+0.10 (0.38%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $26.19 +0.02 (0.08%) 4:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (150 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for SRDX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Surmodics, Inc falls in the month of September.

All items in Millions except Per Share data.

9/30/2023 9/30/2022 9/30/2021 9/30/2020 9/30/2019
Assets          
Cash & Equivalents 45 19 39 61 55
Receivables 11 13 11 10 10
Notes Receivable 0 0 0 0 0
Inventories 15 12 7 6 5
Other Current Assets 15 14 14 9 12
Total Current Assets 87 58 70 87 81
Net Property & Equipment 26 27 30 30 30
Investments & Advances 0 0 2 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 6 7 6
Intangibles 69 69 83 40 40
Deposits & Other Assets 4 5 4 4 2
Total Assets 186 158 195 169 160
Liabilities & Shareholders Equity 9/30/2023 9/30/2022 9/30/2021 9/30/2020 9/30/2019
Notes Payable 0 0 0 0 0
Accounts Payable 3 3 2 2 2
Current Portion Long-Term Debt 0 10 10 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 17 15 13 12 9
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 4 4 5 5 9
Total Current Liabilities 24 32 30 19 20
Mortgages 0 0 0 0 0
Deferred Taxes/Income 4 7 13 11 12
Convertible Debt 0 0 0 0 0
Long-Term Debt 29 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 8 11 12 8 6
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 66 50 55 38 37
Shareholders Equity 9/30/2023 9/30/2022 9/30/2021 9/30/2020 9/30/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 1 1
Capital Surplus 37 29 22 15 11
Retained Earnings 87 89 116 112 111
Other Equity -5 -10 2 3 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 120 108 140 131 123
Total Liabilities & Shareholder's Equity 186 158 195 169 160
Total Common Equity 120 108 140 131 123
Shares Outstanding 14.10 13.90 13.80 13.60 13.40
Book Value Per Share 8.50 7.80 10.15 9.64 9.14

Fiscal Year End for Surmodics, Inc falls in the month of September.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 35 45 45 19
Receivables NA 13 11 12 12
Notes Receivable NA 0 0 0 0
Inventories NA 14 15 15 14
Other Current Assets NA 17 15 15 16
Total Current Assets NA 80 87 86 61
Net Property & Equipment NA 26 26 27 28
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 71 69 72 73
Deposits & Other Assets NA 4 4 5 5
Total Assets NA 180 186 189 166
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 3 3 2 4
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 10 17 13 12
Income Taxes Payable NA 0 0 12 0
Other Current Liabilities NA 4 4 4 3
Total Current Liabilities NA 16 24 32 19
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 4 4 6 5
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 29 29 29 29
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 8 10 10
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 58 66 76 64
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 1 1 1 1
Capital Surplus NA 38 37 34 32
Retained Earnings NA 86 87 81 73
Other Equity NA -3 -5 -3 -4
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 122 120 112 103
Total Liabilities & Shareholder's Equity NA 180 186 189 166
Total Common Equity 0 122 120 112 103
Shares Outstanding 14.20 14.20 14.10 14.10 14.10
Book Value Per Share 0.00 8.60 8.50 7.97 7.27